Design Therapeutics, Inc.
DSGN
$15.62
-$0.17-1.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 14.38M | 13.43M | 14.59M | 15.74M | 15.38M |
| Gross Profit | -14.38M | -13.43M | -14.59M | -15.74M | -15.38M |
| SG&A Expenses | 5.33M | 4.74M | 4.72M | 5.83M | 5.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.71M | 18.17M | 19.31M | 21.57M | 20.42M |
| Operating Income | -19.71M | -18.17M | -19.31M | -21.57M | -20.42M |
| Income Before Tax | -17.64M | -16.00M | -17.00M | -19.08M | -17.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.64M | -16.00M | -17.00M | -19.08M | -17.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.64M | -16.00M | -17.00M | -19.08M | -17.72M |
| EBIT | -19.71M | -18.17M | -19.31M | -21.57M | -20.42M |
| EBITDA | -19.55M | -18.01M | -19.16M | -21.42M | -20.26M |
| EPS Basic | -0.29 | -0.27 | -0.30 | -0.34 | -0.31 |
| Normalized Basic EPS | -0.18 | -0.17 | -0.19 | -0.21 | -0.20 |
| EPS Diluted | -0.29 | -0.27 | -0.30 | -0.34 | -0.31 |
| Normalized Diluted EPS | -0.18 | -0.17 | -0.19 | -0.21 | -0.20 |
| Average Basic Shares Outstanding | 61.43M | 58.74M | 56.95M | 56.86M | 56.76M |
| Average Diluted Shares Outstanding | 61.43M | 58.74M | 56.95M | 56.86M | 56.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |